You Won't Believe What Just Happened: Vietnam Approves Shocking First-Ever Enterovirus Vaccine!

Medigen Vaccine Biologics Corp. (MVC), a Taiwanese company, has made a significant breakthrough in the fight against Enterovirus 71 (EV-A71) with the recent approval of its vaccine, ENVACGEN®, by the Vietnamese government. This marks the first marketing authorization for an EV-A71 vaccine in Vietnam, a country where the virus has caused severe neurological complications and fatalities in young children.

In a strategic move to expand its reach in the Southeast Asian market, MVC has partnered with Substipharm Biologics, based in Paris. This collaboration is particularly important in addressing a critical need for pediatric health solutions in the region. In Vietnam alone, there were approximately 180,000 reported cases of EV-A71 in 2023, resulting in 31 deaths. The urgency for effective vaccination is clear, especially given the increasing incidence of hand, foot, and mouth disease (HFMD), which saw a staggering 28.9% rise in 2025.

The ENVACGEN® vaccine boasts an impressive 100% efficacy rate in clinical trials, effectively protecting infants as young as two months. Notably, the vaccine's immunogenicity is expected to last over five years. Given Vietnam's annual birth rate of 1.36 million, MVC and Substipharm are well-positioned to meet the anticipated demand.

Leo Lee, CEO of MVC, emphasized the importance of ENVACGEN® in MVC's broader mission to enhance global health. He stated, “This vaccine marks a pivotal moment not only for MVC but also for the health of children across Southeast Asia.” Meanwhile, Fabrice Baschiera, CEO of Substipharm Biologics, highlighted the urgent need for effective interventions against the rising threat of EV-A71, underscoring the collaboration's potential impact on public health.

Founded in 2012, MVC has established itself as a leader in vaccine innovation, with facilities certified by the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The company has developed a diverse portfolio that includes vaccines for both enteroviruses and influenza. Its role as Taiwan’s sole domestic manufacturer with Emergency Use Authorization during the COVID-19 pandemic further solidified its reputation in the field.

Substipharm, which distributes over 90 products in more than 100 countries, has recently expanded into biologics with the introduction of IMOJEV®, a vaccine for Japanese encephalitis. This move into biologics aligns with the company's operational presence in key markets like Switzerland, Thailand, and Vietnam, enhancing its influence in the Asia-Pacific region.

The approval of ENVACGEN® represents more than just a new vaccine; it signifies a crucial step towards safeguarding the health of children in Vietnam and potentially other Southeast Asian nations facing similar public health challenges. As pediatric healthcare continues to evolve, the collaboration between MVC and Substipharm may pave the way for further innovations in vaccine development, ultimately aiming to reduce the burden of EV-A71 and improve health outcomes for vulnerable populations.